Clinical efficacy of apatinib in treating refractory triple-negative advanced breast cancer / 中国肿瘤临床
Chinese Journal of Clinical Oncology
; (24): 769-772, 2017.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-608854
Biblioteca responsável:
WPRO
ABSTRACT
Objective:
To evaluate the effectiveness and safety of using apatinib in the treatment of refractory triple-negative advanced breast cancer.Methods:
Eight cases of advanced triple-negative breast cancer patients confirmed via histopathology, who were previously treated with anthracycline, taxane, gemcitabine, capecitabine, and 500 mg/d apatinib in our hospital from July 2015 to November 2016, were retrospectively analyzed. The time of disease progress, effective rate, clinical benefits, and side effects were observed.Results:
Eight patients were administrated with an average of 4 treatment cycles, and the effects were evaluated after 2 weeks. Four patients exhibited partial remission, 3 had a stable disease, and 1 had a progressive disease. The disease control rate was 87.5%, and the median progression free survival was 4.2 months. The main side effects were hand-foot syndrome (3/8), bone marrow arrest (4/8), hypertension (2/8), proteinuria (3/8), hemoptysis (1/8), nausea (2/8), and fatigue (2/8). Most of these side effects were tolerable.Conclusion:
Apatinib can effectively and tolerably prolong survival time and improve the quality of life of patients with advanced triple-negative breast cancer.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Aspecto:
Preferência do paciente
Idioma:
Chinês
Revista:
Chinese Journal of Clinical Oncology
Ano de publicação:
2017
Tipo de documento:
Artigo